PAVmed Inc (PAVM) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Growth Initiatives [Yahoo! Finance]
PAVmed Inc. (PAVM)
US:NASDAQ Investor Relations:
ir.pavm.com
Company Research
Source: Yahoo! Finance
EsoGuard Test Volume: 3,664 tests, a 29% increase from Q3 2025. Cash Burn Rate: $1.5 million for Q4 2025. Equity Method Investment in Lucid: $34 million at year-end 2025. Lucid Shareholding: PAVmed holds approximately 31 million shares, representing an 18% ownership. Net Loss: $2.8 million GAAP net loss for Q4 2025 before noncontrolling interest and preferred dividends. Non-GAAP Loss: $942,000 for Q4 2025. Operating Expenses: Nearly flat since Lucid deconsolidation in 2024. Warning! GuruFocus has detected 6 Warning Signs with PAVM. Is PAVM fairly valued? Test your thesis with our free DCF calculator. Release Date: March 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points PAVmed Inc ( NASDAQ:PAVM ) successfully completed a restructuring recapitalization and financing, removing toxic convertible securities and achieving a clean capital structure. Lucid, a subsidiary of PAVmed Inc ( NASDAQ
Show less
Read more
Impact Snapshot
Event Time:
PAVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PAVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PAVM alerts
High impacting PAVmed Inc. news events
Weekly update
A roundup of the hottest topics
PAVM
News
- PAVmed (PAVM) had its price target lowered by Ascendiant Capital Markets from $510.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
- Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- How The PAVmed (PAVM) Narrative Is Shifting After The Latest Analyst Reassessment [Yahoo! Finance]Yahoo! Finance
- PAVmed (PAVM) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PAVM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold".MarketBeat
- PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio [Yahoo! Finance]Yahoo! Finance
PAVM
Earnings
- 11/13/25 - Beat
PAVM
Sec Filings
- 4/14/26 - Form SCHEDULE
- 4/13/26 - Form 4
- 4/13/26 - Form 3
- PAVM's page on the SEC website